Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00816361 · ClinicalTrials.gov registry record · Phase 1
A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT00816361 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 43 participants.
The verdict
NCT00816361, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
Evaluate the safety and tolerability of MEDI-573 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
Interventions
- DRUG MEDI-573
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2009-03-09 |
| Est. Completion | 2012-09-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00816361
The ClinicalTrials.gov registry entry for NCT00816361 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI-573 is the first listed.
NCT00816361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00816361 about?
NCT00816361 is a clinical study titled "A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors". Evaluate the safety and tolerability of MEDI-573 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
What is the current status of trial NCT00816361?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2009-03-09. Estimated completion is 2012-09-11.
What interventions are being tested in trial NCT00816361?
The interventions under investigation include: MEDI-573 (DRUG).
Who is sponsoring clinical trial NCT00816361?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.